Use of lithium ascorbate in middle-aged individuals with cognitive dysfunction
Abstract
A study evaluating the use of lithium ascorbate in the treatment of cognitive dysfunction involved 200 patients with cerebrovascular disease (mean age 52 years, 92 men, 108 women). Participants were divided into two groups: main (n = 100) — conventional therapy (vascular, nootropic) + lithium ascorbate (at a dose of 780 mg/day) and control (n = 100) — conventional therapy only. The treatment continued for 2 months. In all patients, the level of Li in the hair, the amount of brain-derived neurotrophic factor (BDNF) in the blood plasma, and the neuropsychological status were assessed before and after treatment.
It was found that the use of lithium ascorbate in combination with conventional therapy contributed to a significant increase in working efficiency, BDNF level, to mood improvement, as well as an increase in the quality of life of patients in the main group.
Supporting agencies: The study was supported by a grant of Russian Foundation for Basic Research No. 19-07-00356
About the Authors
E. V. Yanko
Kemerovo State University
Russian Federation
Russian Federation
Yanko Evgeniy Vladimirovich — Cand. Sci. (Psych.), Associate Professor, Department of Social Psychology and Psychosocial Technologies.
Kemerovo
E. G. Pepelyaev
Kemerovo State Medical University
Russian Federation
Russian Federation
Pepelyaev Evgeniy Gennadievich — Post-graduate Student, Department of Neurology, Neurosurgery, Medical Genetics and Medical Rehabilitation.
22а, Voroshilova str., Kemerovo, 650056
G. N. Vedmed
Kuzbass Clinical Hospital for War Veterans
Russian Federation
Russian Federation
Vedmed Galina Nikolayevna — Cand. Sci. (Med.), Head, Neurological Department.
Kemerovo
V. A. Semenov
Kemerovo State Medical University
Russian Federation
Russian Federation
Semenov Vladimir Aleksandrovich — Dr. Sci. (Med.), Professor, Department of Neurology, Neurosurgery, Medical Genetics and Medical Rehabilitation.
Kemerovo
References
1. Starchina Yu.A., Parfenov V.A. (2008). Cognitive disorders in cerebrovascular diseases: diagnosis and treatment. Neurology, 16 (12), 1-3. In Russ.
2. Petersen R.S., Smith G.E., Waring S.C. et al. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol., 6 (3), 303-308.
3. Parfenov V.A., Zakharov V.V., Preobrazhenskaya I.S. (2014). Cognitive Disorders. Moscow, 192 p. In Russ.
4. Zakharov V.V. (2006). All-Russia epidemiological and therapeutic investigation concerning cognitive impairment in the elderly (“Prometheus”). Neurological Journal, 11 (2), 27-32.
5. Subbotin АА., Semenov V.A, Getmanenko I.M., Korotkevich N.A, Arefeva E.G. (2009). The diagnostics of cognitive disorders in the early stages of cerebrovascular diseases. Clinical Neurology, 4, 25-27.
6. Yakhno N.N., Koberskaya N.N., Damulin I.V., Zakharov V.V., Mkhitaryan Е.А. (2006). The organization of medical care for patients with memory disorders and other types of cognitive impairment. Neurological Journal, 11 (1), 75-79.
7. Agadzhanyan N.A, Skalnyj AV. (2001). Chemical Elements in the Environment and the Ecological Portrait of a Human. 2nd ed. Moscow, 83 p. In Russ.
8. Leibrock J., Lottspeich F., Hohn A. et al. (1989). Molecular cloning and expression of brain-derived neurotrophic factor. Nature, 34 (1), 149-152.
9. Castren E., Voikar V., Rantamaki T. (2007). Role of neurotrophic factors in depression. Curr. Opin. Pharmacol., 7(1), 18-21. doi: 10.1016/j.coph.2006.08.009.
10. Serkina E.V., Gromova О.А., Torshin I.Yu., Sotnikov N.Yu., Nikonov А.А. (2008). Cerebrolysin alleviates perinatal CNS disorders through modulation and antioxidant protection. S.S. Korsakov Journal of Neurology and Psychiatry, 108 (11), 62-66.
11. Torshin I.Yu., Gromova О.А., Mayorova L.A, Volkov AYu. (2017). Targeted proteins involved in the neuroprotective effects of lithium citrate. Neurology, Neuropsychiatry, Psychosomatics, 9 (1), 78-83. doi: 10.14412/2074-2711-2017-1-78-83.
12. Torshin I.Yu., Gromova О.А., Kovrazhkina Е.А. et al. (2017). Data minings of the interactions between the trace element composition of blood and the state of the patients with the lateral amyotrophic sclerosis shown lowered levels of lithium and selenium. Consilium Medicum, 19 (9), 88-96. doi: 10.26442/2075-1753_19.9.88-96.
13. Ostrenko RS., Gromova О.А., Pronin AV. et al. (2017). Neuroprotective and adaptogenic effects of lithium ascorbate: studies in in vivo models and in vitro. Problems of Productive Animals Biology, 3, 37-47.
14. Ostrenko К.У., Gromova О.А., Sardaryan I.S. et al. (2017). Efficiency of lithium ascorbate on the model of chronic alcohol intoxication. Pharmacokinetics and Pharmacodynamics, 1, 11-21.
15. Volkov А.Yu., Toguzov R.T. (2002). Trace Elements in Medicine. Мoscow, 230 p. In Russ.
Review
For citations:
Yanko E.V., Pepelyaev E.G., Vedmed G.N., Semenov V.A. Use of lithium ascorbate in middle-aged individuals with cognitive dysfunction. Journal of Siberian Medical Sciences. 2020;(4):38-45.
Views:
345
Email this article 